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The ﬁrst microRNA (miRNA) (lin-4) was identiﬁed in
1993 by Lee et al. (1) in the nematode Caenorhabditis ele-
gans, but many considered this ﬁnding an anomaly, an odd
occurrence in worms. Only after a second one (let-7) was
discovered by the same authors did the interest in miRNAs
arise (2). At that time, however, the role and the importance
of these short, noncoding RNAs were totally unclear, and
many considered them a mystery (2). However, others,
probably bearing in mind that eccentricities are a luxury that
living organisms cannot afford, in particular when highly
conserved through evolution (2), kept studying miRNAs.
Thanks to their efforts, an unknown and fascinating world
of regulations and interactions that control and tune a large
part of our genes is coming to light.
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The role of miRNAs in human diseases was ﬁrst described
in leukemia; then in cancer, diabetes, and immune diseases
(3); and, ﬁnally, in cardiovascular disease (CVD) (4,5). In the
past few years, an explosion of studies on miRNAs in CVD
has led to considerable advances in the ﬁeld, with evidence
that they are involved in cardiac remodeling after myocardial
infarction (MI) (6) and in nonischemic cardiomyopathies (7),
arrhythmias (8), atherosclerosis (9), and myocardial regener-
ation (10). All of these ﬁndings are potentially revolutionary
and may disrupt our knowledge and practice, as miRNAs
might be used as novel therapeutic agents and/or as novel
biomarkers of risk and disease.
We are, however, only beginning the exploration of this
new world and, to conﬁrm or reject the hypothesis that
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remain, including the extent of the role of miRNAs, the safety
of interventions that modify their activity, and the practical
impact of analytical issues. The answers to these questions
may come only from well-designed, carefully conducted,
innovative studies aimed to position more precisely the role of
miRNAs before they enter in the clinical arena.
In this issue of the Journal, Liebetrau et al. (11), taking
advantage of the transcoronary ablation of septal hypertrophy
(TASH) technique for obstructive hypertrophic cardiomy-
opathy, elegantly deﬁne, in humans, the precise time of
appearance in the circulation of speciﬁc candidate miRNAs
(12,13) after coronary occlusion. In previous studies in MI,
miRNAs had been assessed only in the emergency department
or in rodents under experimental conditions. In clinical
practice miRNAs are released at different times after MI
symptoms onset, making it difﬁcult to establish their time
of release from the injuredmyocardium and to rule out the role
of confounders, including previous ischemia, diabetes, left
ventricular dysfunction, and the dynamic nature of coronary
thrombosis. On the other hand, studies in rodents, although
interesting, may barely mimic the condition of naturally
occurring MI in humans and have the limitation of possible
species speciﬁcity of myocardial miRNAs. Therefore, to
establish the role of miRNAs as biomarkers of MI and to
compare them with proven biomarkers such as high-
sensitivity cardiac troponin (hs-Tn), deﬁnitive information
on the release of miRNAs, after coronary occlusion in
humans, in necessary. Liebetrau et al. (11) clearly demonstrate
that, after only 15 min of coronary occlusion, concentrations
of miR-1 and miR-133a are increased and reach a plateau at
75 min. Conversely, miR-208 mildly increases after 105 min
and remains stable afterward, and miR-21 does not change at
all after coronary occlusion.
These ﬁndings raise expectations but also questions: would
miRNAs represent a new gold standard for the diagnosis of
MI? How much more effective are they than hs-Tn? How
speciﬁc are miRNAs for MI? How feasible, fast, and
analytically robust would their assessment be outside of the
protective environment of a molecular-biology laboratory?
Apparently, the most important observation is the stun-
ning precocity of elevation in the peripheral circulations of
miR-1 and miR-133: only 15 min. Similar data have already
been shown in mice after coronary ligation for miR-499-5p,
while, in humans, miR-128, miR-499, and miR-1 were
found elevated after 1 h from symptom onset (12,13). Such
an early appearance of miRNAs might allow a very early
recognition of MI in patients with non–ST-segment eleva-
tion MI, shortening run-in. Interestingly, Liebetrau et al.
(11) also assessed hs-TnT release after TASH and found that
hs-TnT plasma levels were raised more than 50% after 15
min, with a range of increases (3.78 to 38 pg/l) that in many
patients would have been sufﬁcient for the diagnosis of MI
(>14 pg/l) (14); at 30 min, hs-TnT was above this level in all
patients. In other studies, hs-Tn was found to increase just 1
h after symptom onset in patients (12–15) and after 15
Table 1
Comparison of Phases of Biomarker Evaluation
Between hs-Troponin and MicroRNAs
Characteristic hs-Troponin MicroRNAs
Do novel biomarker levels differ
between subject with and
without outcome?
Yes Yes
Does the novel marker predict
future events in prospective
or nested case cohort?
Yes Not known
Does the novel marker add
predictive value to established
risk markers?
Yes Not known
Does the novel marker add
predictive risk sufﬁciently to
change recommended therapy?
Not known Not known
Does use of the novel marker
improve clinical outcomes sufﬁciently
to justify the additional costs of testing?
Not known Not known
Modiﬁed from Hlatkly et al. (22).
hs ¼ high-sensitivity.
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1000minutes in mice (12). Furthermore, the crucial topic with the
current biomarkers of MI is not sensitivity, which is not
lacking in hs-Tn, but speciﬁcity (16). Would miRNAs be, at
the same time, more sensitive and more speciﬁc than hs-Tn?
This is unlikely, as a key property of miRNAs is their ability
to modulate different genes (17); therefore, it is expected that
candidate miRNAs as biomarkers of MI might be increased
also in other conditions. miR-1 elevation has also been found
in cardiac arrhythmias (18) and, together with miR-133a, in
ischemic pre-conditioning (19) and remodeling (20). Other
miRNAs, such as miR-208 and miR-21, are present also in
other tissues, which precludes a high speciﬁcity of these
miRNAs for MI.
Another question that deserves attention is whether
laboratory assessment of miRNAs may soon become as
robust and affordable as is the current assessment of tro-
ponin. There is no doubt that methods for miRNAs’ rec-
ognition and quantiﬁcation will improve with advances in
technologies; however, some pre-analytic problems still need
clariﬁcation, such as the best samples for analysis (serum vs.
plasma vs. whole blood) and the confounder role of heparin,
in particular when polymerase chain reaction is used. These
analytical issues might also explain the fact that some
miRNAs have not been consistently found in MI; for
example, D’Alessandra et al. (12) failed to ﬁnd increased
levels of miR-208, and Liebetrau et al. (11) of miR-21 and
partially of miR-208. It might also be possible that sensi-
tivity to pre-analytical and analytical and/or to clinical
confounders (diabetes, renal insufﬁciency, age) may vary
among different miRNAs. An important limitation of the
study of Liebetrau et al. (11) was that hypertrophic cardio-
myopathy has peculiar muscle differences from normal and
ischemic myocardium; this might, for example, explain the
absence in their study of detectable increases in miR-21.
Recently, Vogel et al. (21), using a whole-genome miRNA
kinetic study, found seven other miRNAs involved as
a signature of MI; this observation suggests that moremiRNAs than supposed until now may be involved as
biomarkers of MI and, consequently, raises the question of
whether a panel of miRNAs would be a better biomarker
than single candidates.
In conclusion, so far, miRNAs hold many promises but
little deﬁnite evidence (Table 1). Fortunately, this area of
investigation is crowded with innovative studies and several
international projects, such as those funded by the European
Community Framework Seventh Proposal, are addressed to
elucidate whether miRNAs may represent an ideal biomarker
of MI and other diseases. In parallel, several groups are
exploring the most revolutionary side of miRNAs: their role
as therapeutic agents (10). Whether miRNAs will deﬁni-
tively move from the mist of an odd mystery to the glory of
a shining star will require more time and well-designed,
scientiﬁcally sound studies, such as the one in this issue of
the Journal, but these efforts are worth being pursued.
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